Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...
Optum is closing its adult medical care office on 10th Street in Secaucus on April 7. Optum's pediatric office at 10th Street ...
Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
Michael Arulfo, CPM, CLP, CSPO, has built a distinguished career at the intersection of enterprise architecture and ...
The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...
Aetna Inc. and OptumHealth Care Solutions Inc. signed a settlement worth $8.35 million that’s aimed at resolving a class ...
Daily Freeman on MSN14d
After Ryan’s call for probe, Optum says it has made improvements at medical facilitiesA healthcare company targeted by U.S. Rep. Pat Ryan as part of a service probe said that its facilities have undergone much in the way of improvement since it acquired them. In a ...
Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...
The “Big Three” PBMs are kicking their suit up to the 8th Circuit and, in the meantime, are once again asking a Missouri district judge to halt the FTC’s administrative case against them.
Vertex Pharmaceuticals’ (VRTX) non-opioid pain drug Journavx was picked up by UnitedHealth’s (UNH) Optum on “Tier 3.” The insurer said, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback